Prenosis, Inc., a Chicago, IL-based AI company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH).
The grants will study the use of Prenosis’s Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients’ health states rapidly evolve in acute care environments.
The grants are titled “Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis”, and “Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map”.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from
In a study published in ‘Scientific Reports’, researchers found that insulin resistance markers TyG-BMI and HOMA-IR effectively predict non-alcoholic fatty liver disease (NAFLD) risks in
Prenosis Awarded Grants to Enable Precision Medicine for Sepsis
by Jasmine Pennic Leave a Comment
What You Should Know:
Alnylam thickened the plot
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here
Small Pharma Announces SPL028 R&D Strategy Update – Psychedelic Alpha
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from
Study identifies key markers for early detection of fatty liver disease in obese and non-obese individuals
In a study published in ‘Scientific Reports’, researchers found that insulin resistance markers TyG-BMI and HOMA-IR effectively predict non-alcoholic fatty liver disease (NAFLD) risks in